PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 35/74

A1

(11) International Publication Number: WO 98/26790

(43) International Publication Date: 25 June 1998 (25.06.98)

(21) International Application Number: PCT/GB97/03460

(22) International Filing Date: 17 December 1997 (17.12.97)

(30) Priority Data:

9626215.9	18 December 1996 (18.12.96)	GB
9626859.4	24 December 1996 (24.12.96)	GB

(71) Applicant *(for all designated States except US)*: STANFORD ROOK LIMITED [GB/GB]; Glen House, 200–208 Tottenham Court Road, London W1P 9LA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ROOK, Graham, Arthur, William [GB/GB]; Stanford Rook Limited, Glen House, 200–208 Tottenham Court Road, London W1P 9LA (GB). STANFORD, John, Lawson [GB/GB]; Stanford Rook Limited, Glen House, 200–208 Tottenham Court Road, London W1P 9LA (GB). ZUMLA, Alimuddin, Ismail [GB/GB]; The Windeyer Building, 46 Cleveland Street, London W1P 6DB (GB).

(74) Agents: WALTON, Seán, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: *MYCOBACTERIUM VACCAE* FOR DOWN–REGULATION OF THE TH2 ACTIVITY OF THE IMMUNE SYSTEM

(57) Abstract

Antigenic and/or immunogenic material derived from *Mycobacterium vaccae* is used to down–regulate Th2 activity of the immune system without up–regulation of Th1 activity. Disorders such as Chronic Fatigue Syndrome, Gulf War Syndrome and Total Allergy Syndrome are treated. The material preferably comprises dead *M. vaccae* cells in a composition which does not include a non–*M. vaccae* antigen, immunogen or allergen.